127 -3 (31/3) 2020 — Sharipova R.G., Zaripova D.Ya., — EFFECTIVENESS OF USING ALEANDRONIC ACID WITH HORMONE REPLACEMENT THERAPY ALONE nAND TOGETHER
EFFECTIVENESS OF USING ALEANDRONIC ACID WITH HORMONE REPLACEMENT THERAPY ALONE nAND TOGETHER
Sharipova R.G. -Bukhara Medical Institute named after Abu Ali ibn Sino.
Zaripova D.Ya. -Bukhara Medical Institute named after Abu Ali ibn Sino.
Resume
The menopausal period is essentially the transition of the body from reproductive age to a new stage for the body of a woman’s old age, often with menopause, which in many cases needs medical correction which using aleandronic acid and hormone replacement therapy alone and together.
Key words: hormone replacement therapy, menopausal hormone therapy, perimenopause, menopause.
First page
529
Last page
531
For citation: Sharipova R.G., Zaripova D.Ya., Effectiveness of using aleandronic acid with hormone replacement therapy alone and together//New Day in Medicine 3(31)2020 529-531 https://cutt.ly/uxF4xcb
List of references
- Col, N.F., Pauker, S.G., Goldberg., R.J. et al. (1999) Individualizing therapy to prevent long term consequences of estrogen deficiency in postmenopausal women. Arch. Intern. Med., 159, 1458-1466.Compston, J.E. (1992) HRT and osteoporosis. Br. Med. Bull.
- Cummings, S.R., Black, D.M. and Nevitt, M.C. (1990) Appendicular bone density and age predict hip fracture in women. J. Am. Med. Assoc., 263, 665-668.
- Devogelaer, J.P., Broll, H., Correa-Rotter, R. et al. (1996) Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
- Ettinger, B., Genant, H.K., Cann, C.E. et al. (1985) Long term estrogen replacement therapy prevents bone loss and fractures. Ann. Intern. Med., 102,319.
- Ettinger, B., Genant, H.K., Steiger, P. et al. (1992) Low dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am. J. Obstet.Gynecol., 166, 479-488.Felson, DT., Zhang, Y., Hannan, M.T. et al. (1993)
- The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med., 329, 1141-1146.Garnero, P., Sornay, R.E. and Chapuy, M.C. (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
- J.Bone Min. Res., 11, 337-349.Genant, H.K., David, M.D., Baylink, J. and Gallagher, J.C. (1989) Estrogens in the prevention of osteoporosis in postmenopausal women. Am. J. Obstet. Gynecol., 161,1842-1856.Heaney, R.P. (1994) The bone- remodellingtransitient: implications for the interpretation of clinical studies of bone mass change. J. Bone Min. Res., 9, 1515-1523.
- Hochberg, M.C., Ross, P.D., Black, D. et al. (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum., 9, 1246-1254.Jeal, W., Barradell, L.B. and McTavish, D. (1997) Alendronate: A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs, 53, 415-434.
- Зарипова Д.Я., Негматуллаева М.Н. Влижие магний дефицит- iioio состояния и дисбаланса стероидных юрмонов жизнеденятеды юсти оргажзма жешщиюк Тиббиётдаяши кун 2019; 3 (27) Стр- 14-18.
- Зарипова Д.Я., НегматуллаеваМ.Н.,Туксанова Д.И. Ролв Але-Нандроновой кислоты (Осталон в лечении перимежпаузаль- iioio остеопороза. Доктор ахборотномаси 2019; 3 Стр- 5155.
- Зарипова Д.Я., Тук.санова Д.И. Опыт применения трансдер- малыкио препарата Лензетто у женщин иерименоиаузаль- iioio возраста с сопутствующими заболеваниями 2(30/2) 2020 г. Стр-286.
- Хатамова М.Т., Солиева Н.К. Актуальные особенности хро- ничесною пиелонефрита у женщин детородного возраста. Тиббиётдаянги кун 3 (27) 2019.